|
Trials Should Deal With Coverage Concerns Sooner, Study Says
Drugmakers’ health economics and outcomes research teams must provide earlier input on clinical trials so the data they generate have a better chance of securing reimbursement for treatments following regulatory approval, a new study concludes.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives